Format

Send to

Choose Destination
See comment in PubMed Commons below
Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31.

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Author information

1
Department of Ophthalmology, Eye Research Center, Rassoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran. drghasemi@yahoo.com

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

PMID:
23722722
PMCID:
PMC3709385
DOI:
10.1038/eye.2013.107
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center